25.84
-0.09(-0.35%)
Currency In USD
| Previous Close | 25.93 |
| Open | 25.93 |
| Day High | 25.99 |
| Day Low | 25.36 |
| 52-Week High | 31.64 |
| 52-Week Low | 11.16 |
| Volume | 537,909 |
| Average Volume | 927,857 |
| Market Cap | 1.2B |
| PE | -11.38 |
| EPS | -2.27 |
| Moving Average 50 Days | 25.25 |
| Moving Average 200 Days | 20.52 |
| Change | -0.09 |
If you invested $1000 in Pacira BioSciences, Inc. (PCRX) since IPO date, it would be worth $323.73 as of May 31, 2025 at a share price of $25.84. Whereas If you bought $1000 worth of Pacira BioSciences, Inc. (PCRX) shares 4 years ago, it would be worth $579.63 as of May 31, 2025 at a share price of $25.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
GlobeNewswire Inc.
May 15, 2025 12:00 PM GMT
-- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 – -- An oral presentation of the data to be featured at the ASGCT Annual Meeting -- BRISB
Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis
GlobeNewswire Inc.
May 06, 2025 12:00 PM GMT
-- Data will be featured at EULAR Annual Congress – BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the
Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis
GlobeNewswire Inc.
May 02, 2025 12:00 PM GMT
Data will be featured at the ASGCT 28th Annual MeetingBRISBANE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform th